PMID- 36805422
OWN - NLM
STAT- MEDLINE
DCOM- 20230406
LR  - 20230425
IS  - 1865-8652 (Electronic)
IS  - 0741-238X (Linking)
VI  - 40
IP  - 4
DP  - 2023 Apr
TI  - Evaluating the Benefits of TACE Combined with Lenvatinib Plus PD-1 Inhibitor for 
      Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
PG  - 1686-1704
LID - 10.1007/s12325-023-02449-6 [doi]
AB  - INTRODUCTION: This study evaluated the efficacy and safety of transarterial 
      chemoembolization (TACE) combined with lenvatinib plus programmed death (PD)-1 
      inhibitor (TACE-L-P) versus TACE combined with sorafenib plus PD-1 inhibitor 
      (TACE-S-P) in the treatment of hepatocellular carcinoma (HCC) with portal vein 
      tumor thrombus (PVTT). METHODS: The clinical data of patients with HCC and PVTT 
      treated with TACE-L-P or TACE-S-P from January 2018 to March 2022 were collected. 
      The Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and 
      modified RECIST (mRECIST) standard were used to evaluate the therapeutic effect. 
      The progression-free survival (PFS) and overall survival (OS) of the two groups 
      were compared. Blood samples were collected before and after treatment to detect 
      the changes of biochemical indicators, and the adverse events (AEs) related to 
      treatment were recorded. RESULTS: A total of 165 patients were included in the 
      study, including 80 patients receiving TACE-L-P treatment and 85 patients 
      receiving TACE-S-P. Patients in the TACE-L-P group had longer median OS 
      (21.7 months vs. 15.6 months, P = 0.0027), longer median PFS (6.3 months vs. 
      3.2 months, P < 0.0001), higher objective response rate (41.25% vs. 30.59%, 
      P = 0.008), and higher disease control rate (86.25% vs. 62.35%, P = 0.008) than 
      those in the TACE-S-P group. Multivariate analysis of the TACE-L-P group showed 
      that VP classification of PVTT, Child-Pugh grade, interleukin-17 (IL-17), 
      vascular endothelial growth factor (VEGF), procalcitonin (PCT), and C-reactive 
      protein (CRP) were independent factors significantly affecting patients' OS 
      (P < 0.05). There was no significant difference in the incidence and severity of 
      AEs between the two groups. CONCLUSION: TACE-L-P treatment can improve the 
      survival of patients with HCC and PVTT with an acceptable safety, but higher 
      inflammatory indicators will affect the therapeutic effect.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer Healthcare Ltd., part 
      of Springer Nature.
FAU - Zou, Xinhua
AU  - Zou X
AD  - Department of Tumor Interventional Therapy, Jiangsu Cancer Hospital and Jiangsu 
      Institute of Cancer Research and, The Affiliated Cancer Hospital of Nanjing 
      Medical University, Nanjing, 210009, Jiangsu, China.
FAU - Xu, Qingyu
AU  - Xu Q
AD  - Department of Tumor Interventional Therapy, Jiangsu Cancer Hospital and Jiangsu 
      Institute of Cancer Research and, The Affiliated Cancer Hospital of Nanjing 
      Medical University, Nanjing, 210009, Jiangsu, China.
FAU - You, Ran
AU  - You R
AD  - Department of Tumor Interventional Therapy, Jiangsu Cancer Hospital and Jiangsu 
      Institute of Cancer Research and, The Affiliated Cancer Hospital of Nanjing 
      Medical University, Nanjing, 210009, Jiangsu, China.
FAU - Yin, Guowen
AU  - Yin G
AD  - Department of Tumor Interventional Therapy, Jiangsu Cancer Hospital and Jiangsu 
      Institute of Cancer Research and, The Affiliated Cancer Hospital of Nanjing 
      Medical University, Nanjing, 210009, Jiangsu, China. jsnjgwy@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230220
PL  - United States
TA  - Adv Ther
JT  - Advances in therapy
JID - 8611864
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - EE083865G2 (lenvatinib)
RN  - 0 (Vascular Endothelial Growth Factor A)
MH  - Humans
MH  - *Carcinoma, Hepatocellular/complications/drug therapy
MH  - *Chemoembolization, Therapeutic/adverse effects
MH  - Immune Checkpoint Inhibitors/therapeutic use
MH  - *Liver Neoplasms/complications/drug therapy
MH  - Portal Vein/pathology
MH  - Retrospective Studies
MH  - *Thrombosis/drug therapy
MH  - Treatment Outcome
MH  - Vascular Endothelial Growth Factor A/therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols
OTO - NOTNLM
OT  - Hepatocellular carcinoma
OT  - Lenvatinib
OT  - PD-1 inhibitor
OT  - Portal vein tumor thrombus
OT  - Sorafenib
OT  - Transarterial chemoembolization
EDAT- 2023/02/23 06:00
MHDA- 2023/04/05 06:42
CRDT- 2023/02/22 09:36
PHST- 2022/12/14 00:00 [received]
PHST- 2023/01/30 00:00 [accepted]
PHST- 2023/04/05 06:42 [medline]
PHST- 2023/02/23 06:00 [pubmed]
PHST- 2023/02/22 09:36 [entrez]
AID - 10.1007/s12325-023-02449-6 [pii]
AID - 10.1007/s12325-023-02449-6 [doi]
PST - ppublish
SO  - Adv Ther. 2023 Apr;40(4):1686-1704. doi: 10.1007/s12325-023-02449-6. Epub 2023 
      Feb 20.